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Introduction
Preeclampsia (PE) is characterized by new-
onset or worsening hypertension and signifi-
cant proteinuria after 20 weeks of gestation 
and still represents a major cause of preterm 
birth and maternal mortality/morbidity 
worldwide (ACOG 2013; Ananth et al. 
2013; Ilekis et al. 2007). Decreased smoking 
prevalence, increasing rates of obesity, chronic 
hypertension, and diabetes in the United 
States are all thought to partly explain the 
increasing trend, though other unknown 
behavioral, genetic, and environmental factors 
certainly play a role (Berg et al. 2009; Ogden 
et al. 2006; Catov et al. 2007).
Phthalates and bisphenol A (BPA) are two 
classes of human-made chemicals produced in 
high volume and used in an immense variety 
of products and applications worldwide. 
Higher molecular weight phthalates, such as 
di(2-ethylhexyl) phthalate (DEHP) and butyl-
benzl phthalate (BBzP), are most commonly 
used as plasticizers in a variety of polyvinyl 
chloride containing products, including 
medical materials, and exposure in humans 
primarily occurs from the consumption of 
contaminated food and water (NRC 2008; 
Pak et al. 2007; Schettler 2006; Wormuth 
et al. 2006). Lower-molecular-weight phthal-
ates, such as diethyl phthalate (DEP) and 
dibutyl phthalate (DBP), are primarily used 
in solvents and adhesives which are found 
in a wide variety of consumer personal care 
products (Duty et al. 2005; NRC 2008). BPA 
is most commonly used in the production of 
epoxy resins and polycarbonate polymers and 
is found in a variety of consumer products 
such as food can linings, water bottles, 
thermal receipts, and water supply pipes. Both 
of these classes of chemicals are easily released 
into the environment, which results in ubiqui-
tous exposures to the general population 
(Calafat et al. 2008; Silva et al. 2004).
Although the specific pathophysiology 
underlying PE remains unclear, it is known 
that PE is associated with abnormal placen-
tation (McElrath et al. 2008; Redman and 
Sargent 2005). The presence of the placenta, 
and particularly trophoblastic cells, is necessary 
for the development of PE. Specifically, limited 
trophoblastic invasion of the maternal decidual 
spiral arteries has been called the “hallmark” 
of PE pathology (Redman and Sargent 2005). 
It has been demonstrated that BPA can affect 
the proliferative process of trophoblastic cells 
through estrogen-related receptor γ (ERRγ1) 
(Morice et al. 2011) and has a dose-dependent 
effect upon apoptosis of primary human cyto-
trophoblast cells via tumor necrosis factor α 
(Benachour and Aris 2009). Phthalates have 
been shown to affect placental gene expression 
(Adibi et al. 2010) in human placental tissue 
and alter activation of peroxisome proliferator–
activated receptor γ (PPARγ) in rat placentas 
(Xu et al. 2008). These results demonstrate 
the potential for both of these toxicants to 
decrease placental growth and disturb function, 
providing plausible mechanisms for heightened 
risk of  developing preeclampsia.
To our knowledge, there has been only 
one small epidemiological study investi-
gating the relationship between BPA and 
preeclampsia (Leclerc et al. 2014) and no 
studies into the role of phthalate exposure 
and this heterogeneous condition. In the 
present study we examined the relationship 
between longitudinally measured urinary 
BPA and phthalate metabolite concentrations 
during gestation and risk of preeclampsia.
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Background: Preeclampsia represents a major cause of maternal mortality and morbidity 
worldwide. Although it is known that the placenta plays a central role in development of preeclampsia, 
investigation into the contribution of environmental toxicants to the risk of preeclampsia has 
been sparse.
oBjectives: In the present study we examined the relationship between longitudinally measured 
urinary BPA and phthalate metabolite concentrations during gestation and preeclampsia.
Methods: A nested case–control study of preterm birth was performed in 2011 from women 
enrolled in a prospective birth cohort study at Brigham and Women’s Hospital in Boston. There 
were 50 cases of preeclampsia as part of this study. Urine samples were analyzed for concentrations 
of BPA and nine phthalate metabolites several times during pregnancy. Adjusted Cox proportional 
hazard models were used to calculate hazard ratios of preeclampsia in association with an inter-
quartile range increase in BPA and phthalate concentrations and were weighted to reflect results 
generalizable to the base population.
results: Adjusted hazard ratios indicated that an interquartile range increase of urinary concen-
trations of BPA (1.53; 95% CI: 1.04, 2.25) and MEP (monoethyl phthalate) (1.72; 95% CI: 
1.28, 2.30) at 10 weeks gestation was associated with onset of preeclampsia, whereas significantly 
elevated hazard ratios were found across gestation for all DEHP [di(2-ethylhexyl) phthalate] metab-
olites. These relationships differed based on infant sex.
conclusions: Urinary concentrations of BPA and several phthalate metabolites were significantly 
associated with increased risk of preeclampsia. If validated, these results indicate an environmental 
contribution of endocrine-disrupting chemicals to preeclampsia and suggest a modifiable means to 
reduce the mortality and morbidity associated with this condition.
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Methods
Study Population
Details of the parent birth cohort have been 
previously described (McElrath et al. 2012). 
Briefly, a total of 2,246 women were recruited 
from 2006 to 2008 at three tertiary care 
academic centers: Brigham and Women’s 
Hospital and Beth Israel Deaconess Medical 
Center in Boston, Massachusetts, and 
University of Pennsylvania in Philadelphia, 
Pennsylvania. In 2011, a nested case–control 
study of singleton preterm birth was selected 
from the Brigham and Women’s Hospital 
participant pool of women (n = 1,648) who 
were originally enrolled as part of this larger 
prospective birth cohort. These women were 
originally recruited at two Brigham and 
Women’s Hospital clinical facilities and one 
private practice facility. This nested case–
control study of preterm birth consisted of 
130 women who delivered at < 37 weeks of 
gestation and 352 randomly selected women 
who delivered at ≥ 37 weeks. Of the 482 
women who were a part of the nested case–
control study, a total of 50 (10.4%) were 
diagnosed with PE. Of the 50 cases of PE, 31 
(62.0%) were diagnosed < 37 weeks gestation. 
The study was approved by the institutional 
review boards of Brigham and Women’s 
Hospital and the University of Michigan.
Maternal spot urine samples were obtained 
at four visits during pregnancy. Initial visit 
samples were collected at median 9.7 weeks 
gestation (range, 4.7–16.1 weeks), visit 2 at 
median 17.9 weeks (range, 14.9–21.9 weeks), 
visit 3 at median 26.0 weeks (range, 
22.9–29.3 weeks), and visit 4 at median 
35.1 weeks (range, 33.1–38.3 weeks). All 
specimens were stored at –80°C until analysis. 
Demographic information was collected at the 
initial visit. Clinically relevant pregnancy char-
acteristics were collected at the initial visit and 
subsequently at three additional time points 
throughout pregnancy.
Definition of Preeclampsia
Preeclampsia was defined as blood pressures 
≥ 140 mmHg systolic or ≥ 90 mmHg diastolic 
after 20 weeks of gestation along with positive 
urinary protein testing (> 300 mg/24 hr or 
protein/creatinine ratio > 0.20). All cases of 
preeclampsia were de-identified and reviewed 
by a panel of the study principle investigators. 
A final diagnosis was assigned only with the 
approval of this panel.
Urinary BPA and Phthalate 
Concentrations
Total BPA (free + conjugated) and nine 
phthalate metabolites [mono(2-ethylhexyl) 
phthalate (MEHP), mono(2-ethyl-5-hydroxy-
hexyl) phthalate (MEHHP), mono(2-
ethyl-5-oxohexyl) phthalate (MEOHP), 
mono(2-ethyl-5-carboxypentyl) phthalate 
(MECPP), mono-benzyl phthalate (MBzP), 
Mono-n-butyl phthalate (MBP), mono-
isobutyl phthalate (MiBP), mono-ethyl 
phthalate (MEP), mono(3-carboxypropyl) 
phthalate (MCPP)] were measured in all 
available urine samples (n = 1,695) by NSF 
International (Ann Arbor, MI), based on 
methods developed by the Centers for Disease 
Control (CDC) (Lewis et al. 2013; Silva et al. 
2007; Ye et al. 2005). Levels below the limit 
of detection (LOD) were kept if a numerical 
value was reported or replaced by dividing the 
LOD by the square root of 2 if no value was 
reported (Hornung and Reed 1990). Urinary 
specific gravity (SG) was measured in all 
samples as an indicator of urine dilution using 
a digital handheld refractrometer (ATAGO 
Company Ltd., Tokyo, Japan). Urinary 
BPA and phthalate concentrations were 
corrected for SG using the following formula: 
Pc = P[(1.015 – 1)]/SG – 1)], where Pc repre-
sents the SG-corrected BPA concentration 
(nanograms per milliliter), P represents the 
measured concentration in urine, 1.015 is the 
median SG of all samples measured, and SG 
represents the SG of the individual sample 
(Meeker et al. 2009). Both uncorrected and 
SG-corrected metabolite levels were log-
normally distributed and were natural log (ln) 
transformed for statistical analysis to more 
closely approximate normality and to reduce 
the likelihood of influential values given the 
skewed distribution.
Statistical Analysis
Analysis was performed using SAS version 9.4 
(SAS Institute Inc., Cary, NC). p-Values 
< 0.05 were used to define statistical signifi-
cance. Sociodemographic characteristics of 
the participating women were described and 
associations between those with and without 
PE were examined using chi-square, Fisher’s 
exact, or Wilcoxon rank-sum test as appro-
priate. Geometric means and standard devia-
tions of SG-corrected BPA and phthalate 
levels at individual visits were calculated, and 
differences by visits between cases and controls 
of preeclampsia were tested using Wilcoxon 
rank-sum test. For all statistical analyses, we 
used inverse probability weightings created 
from the probability of selection from the 
parent study population for cases (90.1%) and 
controls (33.9%) (Ferguson et al. 2015b). This 
adjustment negates the effect of oversampling 
preterm births and makes results generalizable 
to pregnant women in the base Brigham and 
Women’s Hospital cohort population (Jiang 
et al. 2006).
Initially, geometric average BPA and 
phthalate concentrations were calculated 
using the visit 1–visit 3 time point measure-
ments and used in separate Cox proportional 
hazard regression models where PE was the 
outcome. Visit 4 measurements were excluded 
from the average due to a disproportionate 
number of samples available in preterm cases 
compared to controls from that time point. 
Crude models included average urinary SG as 
a covariate. In full models, maternal age, race/
ethnicity (white/African American/other), and 
prepregnancy body mass index (BMI) were 
included a priori, and additional covariates 
were added in a forward step-wise model selec-
tion procedure with inclusion in final models 
if they altered effect estimates by > 10%. 
Additional variables that were considered 
included health insurance category (private/
HMO/self-pay vs. Medicaid/Supplemental 
Security income/MassHealth), maternal 
education, smoking status during pregnancy 
(yes/no), parity (nulliparous/parous), gesta-
tional diabetes (yes/no), prior history of PE 
(yes/no), and use of assisted reproductive 
technology (ART) (yes/no). Windows of 
vulnerability to BPA or phthalate exposure 
were then assessed by fitting separate Cox 
proportional hazard regression models with 
PE as the outcome to calculate hazard ratios 
corresponding to an interquartile range (IQR) 
increase in urinary BPA or phthalate metabo-
lite levels from each individual visit. We addi-
tionally ran models of PE stratified by infant 
sex and by gestational age at disease onset, and 
as a sensitivity analysis we excluded cases of 
superimposed PE.
Results
Demographic and clinical characteristics 
of the total study population and strati-
fied by preeclampsia diagnosis are presented 
in Table 1. In general, our population had a 
mean ± SD age of 32.1 ± 5.4 years, had a BMI 
of 26.3 ± 6.1 kg/m2, were largely Caucasian 
(60.0%), and were highly educated (85.6% 
with post–high school education). Cases of 
preeclampsia in this population had a signifi-
cantly higher BMI at initial visit (31.1 ± 7.6 
vs. 25.7 ± 5.6 kg/m2; p < 0.001), used ART for 
conception (18.0% vs. 8.4%; p = 0.04), had 
gestational diabetes (18.0% vs. 7.2%; p = 0.03), 
and were previously diagnosed with chronic 
hypertension (32.0% vs. 3.7%; p < 0.001). 
Additionally, cases of preeclampsia were 
born earlier (36.1 vs. 38.1 weeks of gestation; 
p < 0.001), weighed less at delivery (2683.9 vs. 
3174.3 g; p < 0.001), and were more likely to 
be female (60.0% vs. 42.5%; p = 0.02).
Geometric mean [95% confidence 
interval (CI)] SG-corrected urinary BPA and 
phthalate metabolite concentrations by study 
visit are presented in Table 2. Variability of 
the phthalate metabolites during pregnancy 
in this population has been previously 
published by our group (Ferguson et al. 
2014). Phthalate metabolites were detected in 
> 99% of samples except for MEHP (95.3%) 
and MCPP (96.8%), whereas total BPA was 
Endocrine-disrupting chemicals and preeclampsia
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detected in 81.9% of samples. Geometric 
mean (95% CI) SG-corrected urinary BPA 
and phthalate metabolite concentrations by 
study visit and stratified by case/control status 
are presented in Table S1. Significant differ-
ences in SG-corrected phthalate levels by PE 
case–control status were detected for MECPP 
at visit 3 (61.1 vs. 36.4 ng/mL; p = 0.004). 
Levels of urinary SG were relatively constant 
across pregnancy with mean ± SD as follows 
for each visit and did not significantly 
differ between cases and controls: visit 1: 
1.017 ± 0.008; visit 2: 1.014 ± 0.008; visit 3: 
1.014 ± 0.008; and visit 4: 1.015 ± 0.007.
Adjusted hazard ratios (HR) and 95% CIs 
for onset of PE in association with an IQR 
increase in BPA and phthalate metabolite 
concentrations are presented in Table 3. 
Elevated HRs were observed in relation to 
an IQR increase in BPA concentration for 
visit 1 (HR = 1.53; 95% CI: 1.04, 2.25). In 
addition, there was a significant interaction 
with fetal sex (inter action term p = 0.005) 
where female fetuses had a greater risk for the 
mother developing preeclampsia compared 
with male fetuses. DEHP metabolites showed 
a consistent, significantly adverse association 
with preeclampsia. IQR increases in averaged 
MEHP (HR = 1.40; 95% CI: 1.03, 1.89) and 
∑DEHP (HR = 1.79; 95% CI: 1.30, 2.46) 
levels were associated with a significant increase 
in the onset of preeclampsia. These adverse 
relationships were consistently observed at 
each time point (except time point 2). We also 
observed a consistent interaction with fetal sex 
with early (visit 1) and averaged DEHP metab-
olite levels where female fetuses were at greater 
risk for the mother developing preeclampsia 
(interaction term p-values ranging from 0.04 
to 0.003). Interestingly, associations between 
an IQR increase in visit 4 DEHP metabolites 
and onset of preeclampsia were consistent, 
significant, and elevated compared with other 
time point biomarker levels, though due to 
the timing of the visit (median, 35.1 weeks), 
50% (n = 25) of the preeclampsia cases had 
delivered before sample collection.
Adjusted HRs stratified by infant sex are 
presented in Table 4. Consistent with our 
findings in our interaction models, among 
females, early exposure to BPA and DEHP 
metabolites resulted in a consistent and 
significant adverse relationship with onset of 
preeclampsia; among males this pattern was 
absent. Results were generally similar among 
female and male fetuses for lower-molecular-
weight phthalates and exposure later in preg-
nancy to BPA or higher-molecular-weight 
phthalate metabolites. Caution should be exer-
cised in interpreting results from this stratified 
population, given the low sample size.
We further explored whether timing 
of disease onset—one method to delineate 
disease severity (earlier usually being more 
severe)—affected the associations. There were 
8 (16.0%) cases of preeclampsia that were diag-
nosed < 34 weeks of gestation in this analysis, 
23 (46.0%) that were diagnosed between 34 
and 37 weeks, and 19 (38.0%) that were diag-
nosed > 37 weeks. Those diagnosed > 37 weeks 
had a consistent, significant relationship 
between higher DEHP metabolites or MEP 
and onset of PE (see Table S2). For those 
diagnosed between 34 and 37 weeks, higher 
BPA had a significant relationship with onset 
of PE. Interestingly, we observed no relation-
ships between BPA or phthalate metabolites 
and onset of PE for those who were diagnosed 
< 34 weeks gestation.
As a sensitivity analysis, we additionally 
ran models after excluding cases of superim-
posed PE (n = 16), presented in Table S3. 
The previous association between BPA and 
PE found at visit 1 was no longer found to 
be significant. Conversely, our previously 
observed significant associations with DEHP 
metabolites, MEP, and MCPP all increased 
in strength.
Discussion
In the present study of pregnant women in 
Boston we found urinary BPA and phthalate 
concentrations were significantly associated 
with onset of preeclampsia. After additional 
stratification by infant sex, we observed 
elevated HRs for females with early exposure 
in gestation (visit 1), in association with BPA 
and DEHP metabolite levels. Additionally, 
we observed this adverse relationship in those 
women who were diagnosed > 34 weeks 
of gestation. To our knowledge this is the 
first study to longitudinally assess BPA and 
phthalate concentrations in relation to onset 
of preeclampsia.
Preeclampsia is a multisystem, hetero-
geneous condition. Although diagnosis of 
Table 1. Weighted baseline characteristics of preeclampsia (PE) diagnosed pregnancies compared to all 
other pregnancies [mean ± SD or n (%)].
Characteristic Total (n = 481) PE (n = 50) No PE (n = 431) p-Valuea
Age (years) 32.1 ± 5.4 32.7 ± 5.8 32.1 ± 5.4 0.72
BMI at initial visit (kg/m2) 26.3 ± 6.1 31.1 ± 7.6 25.7 ± 5.6 < 0.001
Race
White 281 (58.4) 30 (60.0) 251 (58.2) 0.18
African American 77 (16.0) 13 (26.0) 64 (14.9)
Asian 31 (6.4) 1 (2.0) 30 (7.0)
Hispanic 66 (13.7) 4 (8.0) 62 (14.4)
Other 26 (5.4) 2 (4.0) 24 (5.6)
Maternal education (years)b
< 12 18 (3.8) 2 (4.0) 16 (3.8) 0.25
High school/GED equivalent 50 (10.6) 9 (18.0) 41 (9.8)
> 12 403 (85.6) 39 (78.0) 363 (86.4)
Health insurancec
Self-pay or Medicaid/Mass Health 91 (19.4) 10 (20.0) 81 (19.3) 0.85
Private insurance/HMO 379 (80.6) 40 (80.0) 339 (80.7)
Nulliparous 215 (44.7) 26 (52.0) 189 (43.9) 0.33
Smoked during pregnancy 15 (3.1) 4 (8.0) 11 (2.6) 0.06
Use of assisted reproductive technology 45 (9.4) 9 (18.0) 36 (8.4) 0.04
Familial history of type 2 diabetes 221 (45.9) 29 (58.0) 192 (44.6) 0.10
Current diagnosis of gestational diabetes 40 (8.3) 9 (18.0) 31 (7.2) 0.03
Preeclampsia in previous pregnancy 17 (3.5) 9 (18.0) 8 (2.0) < 0.001
History of chronic hypertension 32 (6.7) 16 (32.0) 16 (3.7) < 0.001
Gestational age at delivery 37.9 ± 2.9 36.1 ± 2.9 38.1 ± 2.9 < 0.001
Birth weight 3122.4 ± 741.0 2683.9 ± 773.3 3174.3 ± 720.6 < 0.001
Male infant 268 (55.7) 20 (40.0) 248 (57.5) 0.02
ap-Values were calculated with Wilcoxon rank-sum test, chi-square test, or Fisher’s exact test where appropriate 
between preeclampsia status. bn = 10 missing. cn = 11 missing.
Table 2. Specific gravity–corrected urinary BPA and phthalate concentrations (ng/mL) [GM (95% CI)].
Analyte Visit 1 (n = 479) Visit 2 (n = 422) Visit 3 (n = 412) Visit 4 (n = 380)
BPA 1.34 (1.24, 1.45) 1.29 (1.20, 1.40) 1.39 (1.28, 1.51) 1.32 (1.22, 1.43)
MEHP 12.7 (11.3, 14.3) 11.3 (10.1, 12.7) 9.8 (8.8, 11.0) 9.9 (8.8, 11.3)
MEHHP 40.8 (36.3, 45.9) 34.1 (30.6, 38.1) 27.1 (24.1, 30.6) 34.8 (30.8, 39.3)
MEOHP 20.1 (17.9, 22.5) 18.2 (16.3, 20.2) 15.8 (14.0, 17.8) 20.1 (17.8, 22.6)
MECPP 51.8 (46.2, 58.0) 42.9 (38.4, 48.1) 38.5 (34.1, 43.4)* 48.7 (43.1, 55.1)
∑DEHPa 0.46 (0.41, 0.51) 0.39 (0.35, 0.43) 0.33 (0.30, 0.37) 0.41 (0.37, 0.46)
MBzP 6.9 (6.3, 7.7) 7.0 (6.2, 7.7) 6.9 (6.2, 7.7) 7.9 (7.0, 8.8)
MBP 17.9 (16.5, 19.5) 18.3 (16.7, 20.0) 17.4 (15.7, 19.2) 19.9 (18.3, 21.7)
MiBP 7.3 (6.8, 7.8) 7.2 (6.6, 7.8) 7.3 (6.7, 7.9) 9.0 (8.3, 9.8)
MEP 140.8 (123.2, 160.9) 146.5 (126.0, 170.4) 140.0 (120.6, 162.6) 147.4 (125.3, 173.4)
MCPP 2.3 (2.0, 2.5) 2.3 (2.0, 2.6) 1.9 (1.7, 2.2) 2.1 (1.9, 2.3)
GM, geometric mean.
anmol/L. *p < 0.05 between cases and controls Wilcoxon rank-sum test.
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preeclampsia is defined as new onset or wors-
ening hypertension in the presence of signifi-
cant proteinuria, neither of these conditions is 
specific to the pathophysiology of the disease 
(Rana et al. 2013).
It is generally agreed that the placenta 
(specifically trophoblast cells) is the root 
cause of this condition. Redman and Sargent 
(2005) broadly classified two categories of this 
disease: placental preeclampsia and maternal 
preeclampsia. In placental preeclampsia the 
placenta suffers from hypoxic conditions 
(arising from poor placentation) and under-
goes extensive oxidative stress as pregnancy 
develops. Those with placental preeclampsia 
generally deliver earlier and manifest more 
severe symptoms of the disease. In maternal 
preeclampsia preexisting or underlying 
maternal conditions can lead to an abnormal 
maternal response to an otherwise normal 
pregnancy. These categories may arise inde-
pendently or in combination. Additionally, 
Rana et al. (2013) have observed that 
profiles of angiogenic factors are related to 
preeclampsia and differences in these profiles 
may indicate similar categories to the disease 
that Redman and Sargent describe. Recently, 
Ferguson et al. (2015a) observed that DEHP 
metabolites and BPA were both related to 
increases in the ratio of sFlt-1 (soluble fms-like 
tyrosine kinase-1) to PLGF (placental growth 
factor), suggesting a plausible mechanistic link 
between increased exposure and heightened 
risk of placental preeclampsia. It is inter-
esting to speculate that observations in this 
study not only support findings in Ferguson 
et al. (2015a) but may also suggest that these 
 endocrine- disrupting chemicals are also related 
to maternal preeclampsia as well.
In a small cross-section study of women at 
delivery Leclerc et al. (2014) found elevated 
BPA concentrations in placentas, but not 
maternal or cord serum, of preeclamptic 
women versus normotensive controls. This 
same research group and others have also 
found that low BPA concentrations can 
induce apoptosis and inflammation in human 
trophoblastic cells in vitro, providing a poten-
tial mechanistic link of BPA to the patho-
physiology of preeclampsia (Benachour and 
Aris 2009; Morice et al. 2011). Additionally, 
we observed that BPA exposure can alter 
angiogenic profiles, increasing the s-Flt/PlGF 
ratio, which Rana et al. (2013) have related 
to more severe versions of PE (Ferguson 
et al. 2015a). In our present study we found 
a significantly elevated hazard to developing 
preeclampsia in relation to visit 1 (median, 
gestational week 10.1) BPA levels, but this 
relationship was not observed with either 
averaged or other visit specific concentra-
tions. Although it is plausible that timing of 
exposure to BPA may be critical for cellular 
damage to occur, albeit gestational week 6–12 
coincides with significant trophoblastic cell 
remodeling, we cannot rule out the potential 
for chance findings at this time point. To our 
knowledge there has been no epidemiological 
study into the effects of phthalate exposure 
upon risk of preeclampsia.
In our subset analysis we observed a sex-
specific susceptibility to BPA and phthalate 
exposure and onset of PE. Endocrine-
disrupting effects of BPA and phthalates 
are well studied, and multiple animal and 
human studies have reported evidence of 
sex-specific adverse health effects resulting 
from exposure to either of these chemicals 
(Ashley-Martin et al. 2014; Braun et al. 
2011; Cantonwine et al. 2015; Kubo et al. 
2003). It has also been observed that there 
are sexually dimorphic responses with regard 
to placental function and placental disorders 
(Mao et al. 2010; Muralimanoharan et al. 
2013; Osei-Kumah et al. 2011; Sood et al. 
2006). Although our findings of sex-specific 
susceptibility to BPA/phthalate exposure and 
onset of PE are plausible, we acknowledge 
that with our limited sample size these may 
be chance findings.
Our study had several strengths, including 
a repeated time point assessment of BPA 
and phthalate exposure, ultrasound dating 
of gestational age, the ability to control for 
socioeconomic and clinical factors, and 
a physician panel to validate diagnosis and 
timing of onset of PE. Still, results from our 
secondary analyses of stratification upon 
infant sex, timing of disease onset, and visit 4 
analysis should be interpreted in the context 
of the design, given that we were limited 
in our number of PE cases and are likely to 
be underpowered to detect subtle relation-
ships. There was also no control for multiple 
comparisons, which may lead to an inflated 
type 1 error rate. We acknowledge that the 
few significant associations found in relation 
to BPA, MEP, and MCPP exposure may 
be attributable to chance alone and larger 
follow-up studies to replicate the findings 
Table 4. Adjusted hazard ratios (95% CIs) for onset of preeclampsia in association with an interquartile 
range increase in BPA and phthalate metabolite concentrations (ng/mL) stratified by infant sex.
Average (visit 1–3) Visit 1 Visit 2 Visit 3
Females
n (cases, controls) (30, 170) (30, 170) (25, 156) (27, 153)
BPA 1.37 (0.87, 2.16) 1.58 (1.20, 2.08)* 1.10 (0.77, 1.57) 0.81 (0.55, 1.17)
MEHP 1.67 (1.16, 2.42)* 1.55 (1.14, 2.12)* 1.28 (0.84, 1.94) 1.41 (0.98, 2.03)
%MEHP 0.84 (0.57, 1.24) 0.80 (0.61, 1.05) 0.79 (0.51, 1.23) 0.82 (0.64, 1.05)
∑DEHP 2.10 (1.44, 3.07)* 1.88 (1.34, 2.65)* 1.44 (0.94, 2.20) 1.75 (1.19, 2.58)*
MBzP 0.91 (0.57, 1.43) 1.00 (0.66, 1.51) 1.12 (0.62, 2.00) 0.82 (0.50, 1.36)
MBP 1.22 (0.71, 2.11) 1.35 (0.86, 2.11) 0.86 (0.39, 1.89) 1.16 (0.65, 2.10)
MiBP 0.68 (0.40, 1.14) 1.27 (0.85, 1.91) 0.41 (0.18, 0.92)* 0.59 (0.41, 0.85)*
MEP 1.44 (0.97, 2.15) 1.87 (1.32, 2.64)* 1.19 (0.75, 1.88) 1.14 (0.72, 1.81)
MCPP 0.96 (0.67, 1.36) 1.11 (0.87, 1.43) 0.56 (0.32, 0.98)* 1.58 (1.04, 2.42)*
Males
n (cases, controls) (20, 236) (20, 235) (17, 210) (17, 206)
BPA 0.67 (0.26, 1.71) 0.89 (0.38, 2.08) 1.37 (0.47, 3.97) 0.48 (0.18, 1.24)
MEHP 0.93 (0.52, 1.66) 0.84 (0.50, 1.42) 1.05 (0.57, 1.93) 1.24 (0.70, 2.20)
%MEHP 0.58 (0.37, 0.90)* 0.56 (0.34, 0.92)* 1.00 (0.66, 1.51) 0.69 (0.39, 1.23)
∑DEHP 1.21 (0.64, 2.26) 1.13 (0.66, 1.96) 1.05 (0.56, 1.96) 1.55 (0.84, 2.86)
MBzP 1.07 (0.55, 2.07) 0.96 (0.47, 1.95) 1.19 (0.55, 2.54) 1.55 (0.68, 3.51)
MBP 1.09 (0.63, 1.90) 1.09 (0.63, 1.89) 1.20 (0.65, 2.24) 1.13 (0.57, 2.23)
MiBP 1.23 (0.60, 2.52) 1.40 (0.65, 3.04) 1.88 (0.75, 4.69) 0.88 (0.38, 2.01)
MEP 1.32 (0.71, 2.47) 1.50 (0.88, 2.56) 1.05 (0.49, 2.27) 1.07 (0.52, 2.19)
MCPP 0.98 (0.54, 1.80) 1.07 (0.65, 1.75) 0.88 (0.50, 1.55) 1.43 (0.74, 2.76)
Models were adjusted for specific gravity, maternal age, race, BMI, and smoking during pregnancy.
*p < 0.05.
Table 3. Adjusted hazard ratios (95% CIs) for onset of preeclampsia in association with an interquartile 
range increase in BPA and phthalate metabolite concentrations (ng/mL).
Analyte 
Average (visit 1–3) 
(50, 406)a
Visit 1 
(50, 405)a
Visit 2 
(42, 366)a
Visit 3 
(44, 359)a
Visit 4b 
(25, 341)a
BPA 1.14 (0.73, 1.79) 1.53 (1.04, 2.25)* 1.12 (0.61, 2.07) 0.68 (0.43, 1.07) 1.44 (0.80, 2.58)
MEHP 1.40 (1.03, 1.89)* 1.26 (0.97, 1.63) 1.14 (0.82, 1.60) 1.38 (1.02, 1.85)* 2.05 (1.35, 3.12)*
%MEHP 0.73 (0.52, 1.03) 0.75 (0.58, 0.97)* 0.90 (0.65, 1.25) 0.78 (0.61, 1.00) 1.17 (0.67, 2.03)
∑DEHP 1.79 (1.30, 2.46)* 1.52 (1.15, 2.00)* 1.24 (0.87, 1.75) 1.70 (1.24, 2.34)* 2.92 (1.61, 5.28)*
MBzP 0.93 (0.64, 1.35) 0.93 (0.65, 1.33) 1.08 (0.69, 1.70) 0.98 (0.63, 1.53) 1.83 (0.59, 5.65)
MBP 1.06 (0.74, 1.53) 1.14 (0.82, 1.56) 0.95 (0.58, 1.56) 1.09 (0.72, 1.65) 2.25 (0.98, 5.19)
MiBP 0.84 (0.58, 1.21) 1.22 (0.86, 1.74) 0.79 (0.49, 1.30) 0.64 (0.46, 0.90)* 1.54 (0.62, 3.82)
MEP 1.40 (1.00, 1.95)* 1.72 (1.28, 2.30)* 1.13 (0.76, 1.67) 1.15 (0.79, 1.68) 0.80 (0.46, 1.39)
MCPP 0.95 (0.71, 1.28) 1.07 (0.86, 1.33) 0.66 (0.45, 1.00) 1.52 (1.07, 2.15)* 2.37 (1.34, 4.18)*
Models were adjusted for specific gravity, maternal age, race, BMI, smoking during pregnancy, and infant sex.
aCases, controls. bIf exposure measure occurred after preeclampsia diagnosis participants were removed from analysis 
(n = 6). *p < 0.05. 
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are warranted. Although to our knowledge 
this was the first study of preeclampsia to 
use multiple urinary BPA and phthalate 
concentrations from each woman, the low 
temporal reliability of these concentrations 
across pregnancy may indicate that even with 
three to four repeated measures, there may 
still be substantial nondifferential exposure 
measurement error, which would further 
limit  statistical power to detect associations.
Conclusions
In conclusion, we found significant associa-
tions between urinary BPA and phthalate 
concentrations and onset of preeclampsia. 
We found consistent associations between 
DEHP metabolites and preeclampsia across 
pregnancy, with a potential heightened risk 
associated with concentrations later in preg-
nancy. With the relative lack of research into 
the impact of these ubiquitous endocrine-
disrupting chemicals on placental function 
and risk of developing preeclampsia, this study 
highlights a critical need for future research.
RefeRences
ACOG (American College of Obstetricians and 
Gynecologists, Task Force on Hypertension in 
Pregnancy). 2013. Hypertension in pregnancy. 
Report of the American College of Obstetricians 
and Gynecologists’ Task Force on Hypertension in 
Pregnancy. Obstet Gynecol 122:1122–1131.
Adibi JJ, Whyatt RM, Hauser R, Bhat HK, Davis BJ, 
Calafat AM, et al. 2010. Transcriptional biomarkers 
of steroidogenesis and trophoblast differentiation 
in the placenta in relation to prenatal phthalate 
exposure. Environ Health Perspect 118:291–296, 
doi: 10.1289/ehp.0900788.
Ananth CV, Keyes KM, Wapner RJ. 2013. Pre-eclampsia 
rates in the United States, 1980–2010: age-period-
cohort analysis. BMJ 347:f6564, doi: 10.1136/bmj.f6564.
Ashley-Martin J, Dodds L, Arbuckle TE, Ettinger AS, 
Shapiro GD, Fisher M, et al. 2014. A birth cohort 
study to investigate the association between 
prenatal phthalate and bisphenol A exposures and 
fetal markers of metabolic dysfunction. Environ 
Health 13:84, doi: 10.1186/1476-069X-13-84.
Benachour N, Aris A. 2009. Toxic effects of low doses 
of Bisphenol-A on human placental cells. Toxicol 
Appl Pharmacol 241:322–328.
Berg CJ, Mackay AP, Qin C, Callaghan WM. 2009. 
Overview of maternal morbidity during hospi-
talization for labor and delivery in the United 
States: 1993–1997 and 2001–2005. Obstet Gynecol 
113:1075–1081.
Braun JM, Kalkbrenner AE, Calafat AM, Yolton K, 
Ye X, Dietrich KN, et al. 2011. Impact of early-life 
bisphenol A exposure on behavior and executive 
function in children. Pediatrics 128:873–882.
Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. 
2008. Exposure of the U.S. population to bisphenol A 
and 4-tertiary-octylphenol: 2003–2004. Environ 
Health Perspect 116:39–44, doi: 10.1289/ehp.10753.
Cantonwine DE,  Ferguson KK,  Mukherjee B, 
McElrath TF, Meeker JD. 2015. Urinary bisphenol A 
levels during pregnancy and risk of preterm birth. 
Environ Health Perspect 123:895–901, doi: 10.1289/
ehp.1408126.
Catov JM, Ness RB, Kip KE, Olsen J. 2007. Risk of early 
or severe pre-eclampsia related to pre-existing 
conditions. Int J Epidemiol 36:412–419.
Duty SM, Ackerman RM, Calafat AM, Hauser  R. 
2005. Personal care product use predicts urinary 
concentrations of some phthalate monoesters. 
Environ Health Perspect 113:1530–1535, doi: 
10.1289/ehp.8083.
Ferguson KK,  McElrath TF,  Cantonwine DE, 
Mukherjee B, Meeker JD. 2015a. Phthalate metab-
olites and bisphenol-A in association with circu-
lating angiogenic biomarkers across pregnancy. 
Placenta 36:699–703.
Ferguson KK, McElrath TF, Chen YH, Mukherjee B, 
Meeker JD. 2015b. Urinary phthalate metabolites 
and biomarkers of oxidative stress in pregnant 
women: a repeated measures analysis. Environ 
Health Perspect 123:210–216, doi: 10.1289/
ehp.1307996.
Ferguson KK, McElrath TF, Ko YA, Mukherjee B, 
Meeker JD. 2014. Variability in urinary phthalate 
metabolite levels across pregnancy and sensitive 
windows of exposure for the risk of preterm birth. 
Environ Int 70:118–124.
Hornung RW, Reed LD. 1990. Estimation of average 
concentration in the presence of nondetectable 
values. Appl Occup Environ Hyg 5:46–51.
Ilekis JV, Reddy UM, Roberts JM. 2007. Preeclampsia—a 
pressing problem: an executive summary of a 
National Institute of Child Health and Human 
Development workshop. Reprod Sci 14:508–523.
Jiang Y, Scott AJ, Wild CJ. 2006. Secondary analysis 
of case-control data. Stat Med 25:1323–1339.
Kubo K, Arai O, Omura M, Watanabe R, Ogata R, 
Aou S. 2003. Low dose effects of bisphenol A on 
sexual differentiation of the brain and behavior in 
rats. Neurosci Res 45:345–356.
Leclerc F, Dubois MF, Aris A. 2014. Maternal, placental 
and fetal exposure to bisphenol A in women with 
and without preeclampsia. Hypertens Pregnancy 
33:341–348.
Lewis RC, Meeker JD, Peterson KE, Lee JM, Pace GG, 
Cantoral  A, et  al. 2013. Predictors of urinary 
bisphenol A and phthalate metabolite concentrations 
in Mexican children. Chemosphere 93:2390–2398.
Mao J, Zhang X, Sieli PT, Falduto MT, Torres KE, 
Rosenfeld CS. 2010. Contrasting effects of different 
maternal diets on sexually dimorphic gene expres-
sion in the murine placenta. Natl Acad Sci USA 
107:5557–5562.
McElrath TF, Hecht JL, Dammann O, Boggess K, 
Onderdonk A, Markenson G, et al. 2008. Pregnancy 
disorders that lead to delivery before the 28th 
week of gestation: an epidemiologic approach to 
classification. Am J Epidemiol 168:980–989.
McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, 
Troisi  R, et  al. 2012. Longitudinal evaluation of 
predictive value for preeclampsia of circulating 
angiogenic factors through pregnancy. Am  J 
Obstet Gynecol 207:407.e1–407.e7, doi: 10.1016/j.
ajog.2012.08.010.
Meeker JD, Hu H, Cantonwine DE, Lamadrid-
Figueroa  H, Calafat AM, Ettinger AS, et  al. 
2009. Urinary phthalate metabolites in relation 
to preterm birth in Mexico City. Environ Health 
Perspect 117:1587–1592, doi: 10.1289/ehp.0800522.
Morice L, Benaîtreau D, Dieudonné MN, Morvan C, 
Serazin  V,  de  Mazancourt  P,  et   al .  2011. 
Antiproliferative and proapoptotic effects of 
bisphenol A on human trophoblastic JEG-3 cells. 
Reprod Toxicol 32:69–76.
Muralimanoharan S, Maloyan A, Myatt L. 2013. Evidence 
of sexual dimorphism in the placental function with 
severe preeclampsia. Placenta 34:1183–1189.
NRC (National Research Council). 2008. Phthalates and 
Cumulative Risk Assessment: The Tasks Ahead. 
Washington, DC:National Academies Press.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, 
Tabak  CJ, Flegal KM. 2006. Prevalence of 
overweight and obesity in the United States, 
1999–2004. JAMA 295:1549–1555.
Osei-Kumah A, Smith R, Jurisica I, Caniggia I, 
Clifton  VL. 2011. Sex-specific differences in 
placental global gene expression in pregnancies 
complicated by asthma. Placenta 32:570–578.
Pak VM, Nailon RE, McCauley LA. 2007. Controversy: 
neonatal exposure to plasticizers in the NICU. 
MCN Am J Matern Child Nurs 32:244–249.
Rana S,  Schnett ler  WT, Powe C,  Wenger J, 
Salahuddin S, Cerdeira AS, et al. 2013. Clinical 
characterization and outcomes of preeclampsia 
with normal angiogenic profile. Hypertens 
Pregnancy 32:189–201.
Redman CW, Sargent IL. 2005. Latest advances in under-
standing preeclampsia. Science 308:1592–1594.
Schettler T. 2006. Human exposure to phthalates via 
consumer products. Int J Androl 29:134–139.
Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, 
Caudill SP, et al. 2004. Urinary levels of seven 
phthalate metabolites in the U.S. population from 
the National Health and Nutrition Examination 
Survey (NHANES) 1999–2000. Environ Health 
Perspect 112:331–338, doi: 10.1289/ehp.6723.
Silva MJ, Samandar E, Preau JL Jr, Reidy  JA, 
Needham LL, Calafat AM. 2007. Quantification of 22 
phthalate metabolites in human urine. J Chromatogr 
B Analyt Technol Biomed Life Sci 860:106–112.
Sood R, Zehnder JL, Druzin ML, Brown PO. 2006. Gene 
expression patterns in human placenta. Proc Natl 
Acad Sci USA 103:5478–5483.
Wormuth M, Scheringer M, Vol lenweider M, 
Hungerbühler K. 2006. What are the sources of 
exposure to eight frequently used phthalic acid 
esters in Europeans? Risk Anal 26:803–824.
Xu Y, Agrawal S, Cook TJ, Knipp GT. 2008. Maternal 
di-(2-ethylhexyl)-phthalate exposure influences 
essential fatty acid homeostasis in rat placenta. 
Placenta 29:962–969.
Ye X, Kuklenyik Z, Needham LL, Calafat AM. 
2005. Quantification of urinary conjugates of 
bisphenol A, 2,5-dichlorophenol, and 2-hydroxy-
4-methoxybenzophenone in humans by online 
solid phase extraction–high performance liquid 
 chromatography– tandem mass spectrometry. Anal 
Bioanal Chem 383:638–644.
